Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00827
|
|||||
| Drug Name |
Acitretin
|
|||||
| Synonyms |
(2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; Acitretina; Acitretina [Spanish]; Acitretine; Acitretine [French]; Acitretinum; Acitretinum [Latin]; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; All-trans-Acitretin; Etretin; Isoacitretin; Isoetretin; Neotigason; Retinoid etretin; Ro 10-1670; Ro 10-1670/000; Ro 13-7652; Ro-10-1670; Ro-10-1670/000; Ro-13-7652; Soriatane; Soriatane (TN); Soriatane, Acitretin; TMMP; U0279
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Therapeutic Class |
Keratolytic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H26O3
|
|||||
| Canonical SMILES |
CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
|
|||||
| InChI |
InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
|
|||||
| InChIKey |
IHUNBGSDBOWDMA-AQFIFDHZSA-N
|
|||||
| CAS Number |
CAS 55079-83-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 326.4 | Topological Polar Surface Area | 46.5 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
6.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:50173
|
|||||
| TTD Drug ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.